SALIX ANNOUNCES 2021 GASTROINTESTINAL HEALTH SCHOLARS PROGRAM WINNERS

Ten Students Affected by Gastrointestinal Disease Will Each Receive a $10,000 Scholarship

LAVAL, Quebec, July 22, 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program. Ten students living with a GI disease will each receive a $10,000 scholarship; a total of $100,000 in scholarships was awarded.

"We created the Salix Gastrointestinal Health Scholars Program to assist students with GI conditions as they pursue their higher education goals, because we recognize that living with a GI condition can make it challenging and stressful to pursue higher education," said Robert Spurr, president, Salix Pharmaceuticals. "We were moved by the stories this year's recipients shared with us about how they have uniquely had to manage their GI conditions but refused to let them get in the way of their education, and we are honored to help support them."

The 2021 awardees were selected from more than 150 applications. As part of the process, applicants were required to submit essays describing how their GI condition has impacted their educational journey, as well as the role their health care provider played in helping them reach their goals. The applications were reviewed by an independent panel of judges.

The Salix Gastrointestinal Health Scholars Program recognizes students across a wide range of educational pursuits, with scholarships in four categories, including the Undergraduate Scholar Awards for those pursuing undergraduate degrees; the Graduate Scholar Awards for those pursuing graduate degrees; the Working Parent's Scholar Award for parents pursuing undergraduate, vocational/technical or graduate degrees; and the Single Parent's Scholar Award for single parents pursuing undergraduate, vocational/technical or graduate degrees.

The 2021 Salix Gastrointestinal Health Scholars Program recipients are:

- **Undergraduate Scholar Awards**
  - Madeleine Huwe, Sherwood, Ore. – George Fox University
  - Lillian Munro, Ocean Springs, Miss. – The University of Mississippi
  - Yetunde Olateru-Olagbegi, Medford, N.Y. – New York University
  - Amelia Williams, Lafayette, Ind. – Purdue University
- **Graduate Scholar Awards**
  - Madison Folsom, Lancaster, N.Y. – Canisius College
  - Margaux Herrera, El Portal, Fla. – Florida State University
  - Olivia Perez, Coral Gables, Fla. – Nova Southeastern University
  - Blake Sisson, Angier, N.C., – Campbell University
- **Working Parent's Scholar Award**
  - Audriana Duvall, Baltimore, Md. – University of Baltimore
- **Single Parent's Scholar Award**
  - Amy Devlin, Worcester, Mass. – Maharishi International University

"I'm so grateful to receive this scholarship as I pursue my higher education in nursing school," said Madeleine Huwe, a recipient of the Undergraduate Scholar's Award. "It's wonderful to feel seen and imagine my future in health care utilizing my experience as a patient to help improve the system."

To learn more about the Salix Gastrointestinal Health Scholars Program visit **Salix.com/scholarship**.

The 2022 Salix Gastrointestinal Health Scholars Award will begin accepting applications in early 2022.

About Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed

(continued on page 44)

(continued from page 42)

to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey.

For more information about Salix, visit:
Salix.com

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

For more information, visit:
bauschhealth.com

ZEALAND PHARMA PRESENTS DATA ON GLEPAGLUTIDE AT THE 17TH CONGRESS OF THE INTESTINAL REHABILITATION AND TRANSPLANTATION ASSOCIATION (CIRTA)

- ***Company presents three posters, including two on glepaglutide for the treatment of Short Bowel Syndrome (SBS)***
- ***Data demonstrate potential dosing benefits of glepaglutide for patients with SBS***

Copenhagen, DK and Boston, MA, U.S. June 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced it presented three posters at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA), which was held both virtually and in Auckland, New Zealand on June 30-July 2, 2021. The Company's research presented at CIRTA 2021 featured multiple posters related to glepaglutide for the treatment of short bowel syndrome (SBS).

"We presented our research at CIRTA 2021, including data on glepaglutide that suggest dose adjustment may not be necessary when treating SBS patients with renal impairment," said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. "Renal impairment is a common comorbidity in SBS patients that often necessitates adjusting treatment regimen. However, we found no difference in the pharmacokinetic profile of glepaglutide in patients with severe renal impairment, or end stage renal disease, compared to healthy subjects, suggesting that dosage may not need to be adjusted for SBS patients with renal impairment."

Poster Title: Glepaglutide pharmacokinetic profile after single subcutaneous injection in human subjects with varying degrees of renal function
Author: M Askjær Agersnap, K Sonne, K Mark Knudsen, S Wladyslaw
Poster Viewing Reception Date and Time: 30 June-2 July
Abstract Number: 113

Poster Title: Pharmacokinetics and pharmacodynamics of the long-acting GLP-2 analogue after once-weekly dosing in adult healthy subjects
Author: K Sonne, K Mark Knudsen, J Mosolff Mathiesen, G Koefoed Rasmussen, M Berner-Hansen
Poster Viewing Reception Date and Time: 30 June-2 July
Abstract Number: 114

Poster Title: Relation between surgical procedures, chronic intestinal failure and dependency on parenteral support
Author: K Iyer, D Mercer, D Pfeffer, LB Zimmerman, M Berner-Hansen, M Mundi, DL Seidner
Poster Viewing Reception Date and Time: 30 June-2 July
Abstract Number: 116

About Short Bowel Syndrome (SBS)

SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

(continued on page 46)

(continued from page 44)

About Glepaglutide

Glepaglutide is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome (SBS). Glepaglutide is being developed as a ready-to-use liquid product in an autoinjector desiged for convenient and easy subcutaneous administration. Zealand initiated the Phase 3 clinical program for Glepaglutide in October 2018. The pivotal trial is a randomized, double-blind and placebo-controlled study, with both once- and twice-weekly dosing regimens. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand's robust pipeline of investigational medicines includes three candidates in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and has received FDA approval for Zegalogue, (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA).

For more information about Zealand's business and activities, please visit:
zealandpharma.com.

Forward-Looking Statement

This press release contains "forward-looking statements", as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products. These forward-looking statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, the occurrence of adverse safety events; risks of unexpected costs or delays; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this press release and are based on information available to Zealand Pharma as of the date of this release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.